Cousin François, Moïse Martin, Ilbert Cédric, Meunier Paul, Jouret François
Services de Médecine Nucléaire et d'Imagerie Oncologique, CHU Liège, Belgique.
Service de Radiodiagnostic, CHU Liège, Belgique.
Rev Med Liege. 2024 Jun;79(5-6):418-423.
Contrast-induced nephropathy (CIN) is a renal complication occurring after the administration of iodinated contrast agents routinely used in medical imaging. CIN causes acute renal failure of varying severity. The pathophysiology of CIN is probably multifactorial: it involves (i) renal vasoconstriction inducing tissue hypoxia, and (ii) a possible direct toxicity of iodine derivatives leading to tubular inflammation and necrosis. Several risk factors are associated with CIN, some related to the procedure itself, others to the patient's co-morbid profile. In particular, the pre-existence of chronic renal failure, dehydration, congestive heart failure, diabetes or hypotension has been associated with an increased risk of CIN, as summarized in the Mehran score. Prevention of CIN relies essentially on adequate i.v. hydration before and after the procedure, and on the administration of the lowest possible volumes of contrast. In patients at high risk of CIN, the use of metformin and non-steroidal anti-inflammatory drugs is contraindicated at the time of contrast medium i.v. injection. In these patients, renal function assessment after 3-7 days post imaging is required.
对比剂肾病(CIN)是在医学成像中常规使用碘化对比剂后发生的一种肾脏并发症。CIN会导致不同严重程度的急性肾衰竭。CIN的病理生理学可能是多因素的:它涉及(i)肾血管收缩导致组织缺氧,以及(ii)碘衍生物可能的直接毒性导致肾小管炎症和坏死。几种危险因素与CIN相关,一些与检查本身有关,另一些与患者的合并症情况有关。特别是,慢性肾衰竭、脱水、充血性心力衰竭、糖尿病或低血压的预先存在与CIN风险增加有关,如梅兰评分中所总结。CIN的预防主要依赖于检查前后充分的静脉补液,以及使用尽可能低剂量的对比剂。在CIN高风险患者中,静脉注射对比剂时禁忌使用二甲双胍和非甾体抗炎药。在这些患者中,成像后3 - 7天需要进行肾功能评估。